Positioning political buying, disclosed 2026-09-18
Options put/call open interest 0.63, read 2026-10-29
Ethical passes the values gate
Price104.57 USD
Fair value125.31
Ethical score87.2/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-10-15Read Markup99.60+5.0% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-14Read Distribution99.60+5.0% to today Markdown gives way to Distribution after a 6% slide in 4 weeks
2026-09-19Read Markdown105.52-0.9% to today ✓Markup gives way to Markdown with legal news in the headlines
2026-07-20Read Markup100.68+3.9% to today ✓Distribution gives way to Markup after an 11% rise in 3 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Abbott Laboratories holds its Markup at $104.57. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-10-29
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$104.57
Valuation
38.87 trailing · 17.61 forward price to earnings
Values screen
PASS· score 87.2
Beta
0.58
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
15.98%
Below 33%
Interest-bearing debt is just 16.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.69%
Below 33%
Cash held in interest-bearing accounts and securities is 0.7% of assets, under the one-third limit.
Pass
Receivables
18.97%
Below 49%
Money owed to the company is 19.0% of assets, under the 49% limit.
Pass
Revenue purity
0.69%
Below 5%
Only 0.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Abbott Laboratories clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 16%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ABT's ethical verdict changes
Today ABT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads OPPORTUNITY: it trades at roughly a 20% discount to our $125.31 fair value, moderate competitive moat, 14.50% revenue growth.
Fair value range in USD, drawn from the 2026-10-29 screen. The gold marker is the market price at the same screen. A 19.8% margin of safety to the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +15% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Healthcare Giant with Ethical Moat and Growth
When you think of Abbott Laboratories, picture a global health care titan, producing a diverse array of medical devices, nutritional products, and pharmaceuticals that touch millions of lives daily. With strong revenue growth of 13%, Abbott is not just surviving but thriving in the healthcare space. Why it stands out is not just the growth, but its commitment to ethical practices, passing our ethical screen, and a forward P/E of 18.8x, which is reasonable given the growth prospects.
Looking at the financials, Abbott boasts a 12% profit margin and an 11% ROE, indicating solid financial health. Its moderate moat suggests a competitive advantage, though not an unassailable one. The market consensus is bullish, with a median target price of $120, just below our fair value of $126.70, which presents an 11% margin of safety. This valuation, coupled with Abbott's ethical stance, makes it a standout in a crowded healthcare market.
Risks are moderate, as with any company in the healthcare sector; regulatory changes and competitive pressures could impact growth. Additionally, while the company's moat is moderate, it does not guarantee protection against disruptors. However, Abbott's broad product range and commitment to innovation provide a solid foundation for navigating these challenges. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ABT trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$104.68+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119.
2026-10-21Markup$104.68+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markup$104.68+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markup$104.68+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$104.68+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markup$104.68+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markup$104.68+5.1%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markup · changed$99.60+0.0%Entry 11
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-11Markdown$101.29+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.